Research Groups
Induced pluripotent stem cells derived advanced therapies
Dr. Belén Alvarez Palomo leads the iPSC and Advanced Therapies group that develops projects to generate cell therapies, mainly immunological, from induced pluripotent stem cells (iPSC). The main current focus is on the process development for the production of iPSC-derived CAR-NK and macrophages for immunotherapies to treat cancer, and fungal and bacterial infections.
The group is part of the RICORS TERAV network for advanced therapies and of the COST Action HAPLO-IPS for the creation of HLA-homozygous clinical grade iPSC lines.
Members
Cap de grup Ana Belén Álvarez Palomo
Miquel de Homdedeu Cortés
Kenia Rodríguez González
Carles Verdaguer
Karine Tadevosyan
Projects
Publications
-
2026
Scalable and xeno-free protocol for differentiating human induced pluripotent stem cells into functional macrophages
-
2024
Current Landscape of iPSC Haplobanks.
-
2024
An Optimized Method to Produce Human-Induced Pluripotent Stem Cell-Derived Limbal Stem Cells Easily Adaptable for Clinical Use.
-
2023
Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population.
-
2023
Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles.
-
2023
Proteomic Analysis of Human iPSC-Derived Neural Stem Cells and Motor Neurons Identifies Proteasome Structural Alterations.
-
2022
Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells.
-
2021
A synthetic mRNA cell reprogramming method using CYCLIN D1 promotes DNA repair generating improved genetically stable human induced pluripotent stem cells.
-
2021
Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells.
Theses
-
Spatial multi-omics on iPSC-derived CAR-NK effector cells to identify gene modifications with improved anti-tumor performance